文献速递甲状腺核医学肿瘤 PET/CT骨显像与常规 SPECT

镓-68标记LNC1007与2-[氟-18]FDG在转移性分化型甲状腺癌患者评估中的头对头比较研究

[68Ga]Ga-LNC1007 versus 2-[18F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-10-15

本研究纳入10例不明原因高甲状腺球蛋白血症患者和20例明确转移性分化型甲状腺癌患者,均在一周内先后接受[68Ga]Ga-LNC1007与2-[18F]FDG PET/CT。结果显示[68Ga]Ga-LNC1007可检出更多转移灶,真阳性病灶SUVmax与TBR均显著更高,肺和骨转移灵敏度更高,淋巴结诊断特异度和准确度更优,但骨转移特异度低于2-[18F]FDG。

要点

  • 在DmDTC患者中,[68Ga]Ga-LNC1007检出真阳性病灶总数133个,多于2-[18F]FDG的103个。
  • 真阳性病灶SUVmax:总6.30 vs 3.84,淋巴结8.28 vs 4.82,肺3.31 vs 1.49,骨5.73 vs 3.87,均P<0.05。
  • [68Ga]Ga-LNC1007诊断淋巴结特异度96.9% vs 66.7%、准确度96.3% vs 68.5%,均P<0.05。

核心结论

  • 与2-[18F]FDG相比,[68Ga]Ga-LNC1007 PET/CT在转移性分化型甲状腺癌患者中可检出更多转移灶,真阳性病灶SUVmax和TBR更高。
  • [68Ga]Ga-LNC1007诊断淋巴结和肺转移的准确度更好。

研究设计与样本

  • 头对头比较研究,纳入10例不明原因高甲状腺球蛋白血症患者和20例明确转移性分化型甲状腺癌患者。
  • 所有患者均在1周内接受[68Ga]Ga-LNC1007和2-[18F]FDG PET/CT检查。
  • 最终诊断基于组织病理学结果及实验室检查和多模态影像特征的综合评估。
  • 试验注册号ClinicalTrials.gov NCT05515783,注册日期2022年5月1日。

主要发现

  • 在UHTg患者中,[68Ga]Ga-LNC1007 PET/CT检出转移性淋巴结17个 vs 2-[18F]FDG 15个(P=0.317),肺病灶2个 vs 0个。
  • 在DmDTC患者中,[68Ga]Ga-LNC1007检出真阳性病灶总数133个 vs 103个,淋巴结20个 vs 15个,肺18个 vs 10个,骨87个 vs 73个。
  • 真阳性病灶SUVmax:总6.30 vs 3.84,淋巴结8.28 vs 4.82,肺3.31 vs 1.49,骨5.73 vs 3.87,均P<0.05。
  • 真阳性病灶TBR:总6.92 vs 4.93,淋巴结6.48 vs 4.16,肺5.16 vs 2.57,骨7.22 vs 5.41,均P<0.05。
  • 肺转移灵敏度94.7% vs 52.6%,骨转移灵敏度100% vs 83.9%,均P<0.05;淋巴结特异度96.9% vs 66.7%、准确度96.3% vs 68.5%,均P<0.05;骨转移特异度15.4% vs 88.5%,P<0.05。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This head-to-head comparison study aimed to compare the performance of [68Ga]Ga-FAPI-RGD (LNC1007) and 2-[18F]FDG PET/CT in the evaluation of patients with metastatic differentiated thyroid cancer (mDTC). METHODS: Ten unexplained hyperthyroglobulinemia (UHTg) patients and 20 patients with definite metastatic lesions of thyroid cancer (DmDTC) were enrolled in the study. All patients underwent both [68Ga]Ga-LNC1007 and 2-[18F]FDG PET/CT within 1 week. The final diagnosis was based on histopathological results and a comprehensive evaluation of laboratory tests and multimodal imaging characteristics. RESULTS: In patients with UHTg, [68Ga]Ga-LNC1007 PET/CT detected more metastatic lymph nodes (LNs) (17 vs. 15, P = 0.317) and lung lesions (2 vs. 0) than 2-[18F]FDG. In patients with DmDTC, [68Ga]Ga-LNC1007 PET/CT also detected more true positive lesions than 2-[18F]FDG (Total: 133 vs. 103, LN: 20 vs. 15, lung: 18 vs. 10, bone: 87 vs.73). [68Ga]Ga-LNC1007 PET/CT demonstrated significantly higher SUVmax (Total: 6.30 vs. 3.84, LN: 8.28 vs. 4.82, Lung: 3.31 vs. 1.49, Bone: 5.73 vs. 3.87, all P < 0.05) and TBR (Total: 6.92 vs. 4.93, LN: 6.48 vs. 4.16, Lung: 5.16 vs. 2.57, Bone: 7.22 vs. 5.41, all P < 0.05) in true positive lesions compared to 2-[18F]FDG. Specifically, the sensitivity of [68Ga]Ga-LNC1007 PET/CT was higher than that of 2-[18F]FDG in detecting lung and bone metastases (94.7% vs. 52.6% and 100% vs. 83.9%, all P < 0.05). [68Ga]Ga-LNC1007 PET/CT exhibited better specificity and accuracy in diagnosing LNs (96.9% vs. 66.7% and 96.3% vs. 68.5%, all P < 0.05). However, the specificity of [68Ga]Ga-LNC1007 for bone metastasis was inferior to 2-[18F]FDG (15.4% vs. 88.5%, P < 0.05). CONCLUSION: Compared with 2-[18F]FDG, [68Ga]Ga-LNC1007 PET/CT could detect more metastatic lesions, with higher SUVmax and TBR, in patients with mDTC. [68Ga]Ga-LNC1007 had better accuracy in the diagnosis of LN and lung metastasis. Trial registration ClinicalTrials.gov NCT05515783. Registered 01 May 2022. URL of registry https://classic. CLINICALTRIALS: gov/ct2/show/NCT05515783.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen Y, Zheng S, Zang J, et al. [68Ga]Ga-LNC1007 versus 2-[18F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39404790. doi:10.1007/s00259-024-06930-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。